Submitted by Anonymous (not verified) on 5 February 2026 - 14:00
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 20, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 20, Status: Authorised